July 21, 2015 (Reno,  NV) – The Orthopaedic Implant Company (OIC), the leading value innovator in orthopaedic implants, today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) to market the OIC Intramedullary (IM) Nail System.  The OIC IM Nail System consists of hip , antegrade and retrograde femur, trochanteric antegrade femur, and tibial nails.

As with OIC’s existing line of trauma implants, the OIC IM Nail System is modular and designed to reduce over-engineering and inventory requirements offered by name brand competitors.  The result is a set of high-quality instruments and implants that are intuitive by design and in delivery as well.

“Just under 300,000 people over the age of 65 break their hip each year in the U.S.  Offering better value for fracture care in the most cost-sensitive segment of the patient population makes perfect sense,” said Itai Nemovicher, President and CEO of OIC.


About Orthopaedic Implant Company: OIC entered the medical device market in 2010 with an innovative approach to delivering the highest quality implants at the lowest possible price.  OIC implants cost 50 to 60 percent less than the average market price of premium implants, saving health care systems millions of dollars a year.  OIC’s high-quality, low-cost implants and products can be used for a variety of procedures, including treatment of orthopaedic trauma and spinal injuries.  All OIC products are FDA approved and manufactured in FDA approved facilities.